Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 5/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | STAT6 | P42226 | 1/20 | 0.37 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25359331 | 0.79 | — | — | |
| SCHEMBL14287476 | 0.75 | — | — | |
| SCHEMBL13991089 | 0.75 | — | — | |
| SCHEMBL13990989 | 0.75 | GRIN2D (0.43) | GRIN1GRIN2ALMNAGRIN2DGRIN3B | |
| SCHEMBL14040603 | 0.73 | GRIN1 (0.33) | GRIN1GRIN2ALMNAGRIN2DGRIN3B | |
| SCHEMBL14287480 | 0.71 | LMNA (0.42) | GRIN1GRIN2ALMNAGRIN2DGRIN3B | |
| SCHEMBL13559397 | 0.70 | LMNA (0.37) | GRIN1GRIN2ALMNAGRIN2DGRIN3B | |
| SCHEMBL14040661 | 0.67 | — | — | |
| SCHEMBL13990992 | 0.64 | CNR2 (0.33) | — | |
| SCHEMBL14287498 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008130550-A1 | DIAMONDOID DERIVATIVES POSSESSING THERAPEUTIC ACTIVITY IN THE TREATMENT OF NEUROLOGIC DISORDERS | CHEVRON U.S.A, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1982970-A1 | Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders | Chevron USA, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080009546-A1 | Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders | CHEVRON U.S.A. INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009546-A1 | Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders | CHEVRON U.S.A. INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009546-A1 | Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders | CLN6, NLN, CDR2 | GRIN1 557/4885GRIN2A 253/4885LMNA 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.